2. Academic Validation
  3. Regulatory role of CD39 and CD73 in tumor immunity

Regulatory role of CD39 and CD73 in tumor immunity

  • Future Oncol. 2024;20(19):1367-1380. doi: 10.2217/fon-2023-0871.
Nicole Kaplinsky 1,  Kada Williams 1,  Dean Watkins 1,  Molly Adams 1,  Laura Stanbery 2,  John Nemunaitis 2
Affiliations

Affiliations

  • 1 University of Toledo College of Medicine, Toledo, OH 43614, USA.
  • 2 Gradalis, Inc, Dallas, TX 75006, USA.
PMID: 38652041 DOI: 10.2217/fon-2023-0871
Abstract

CD39 is the rate-limiting enzyme for the molecular signal cascade leading to the generation of ADP and adenosine monophosphate (AMP). In conjunction with CD73, CD39 converts adenosine triphosphate (ATP) to ADP and AMP, which leads to the accumulation of immunosuppressive adenosine in the tumor microenvironment. This review focuses on the role of CD39 and CD73 in immune response and malignant progression, including the expression of CD39 within the tumor microenvironment and its relationship to immune effector cells, and its role in antigen presentation. The role of CD39- and CD73-targeting therapeutics and cancer-directed clinical trials investigating CD39 modulation are also explored.

Keywords

CD39; CD73; ENTPD1; adenosine pathway; antigen; immunotherapy; tumor microenvironment.

Figures
Products